BRAF and neoplasm: These results strongly argue in favor of an immunohistochemical approach to exclude Lynch syndrome in microsatellite high (MSI-H) colorectal cancers, as suggested in a very recent publication [25]. BRAF V600E mutation, which is virtually absent in hereditary colorectal cancer, is often present in sporadic CRC that has a CpG island hypermethylation phenotype (CIMP-high), resulting in hypermethylation of promoter regions. BRAF mutated CIMP-high CRC is frequently MSI-H, as the MLH1 promoter has been methylated, resulting in an MLH1-deficient tumor [26].